NCT04083976
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: FGFR
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 2
Drug Category: Tyrosine-Kinase Inhibitor
Key Eligibility Criteria:
Gender: All
Age: 12 Years and older (Child, Adult, Older Adult)
Location of Metastases:
Additional Notes: Patient must have received at least one prior line of systemic therapy in the metastatic setting
Exclusions:
https://ClinicalTrials.gov/show/NCT04083976